MedTrace Logo

MRI Predictors of Response to Tumor Treating Fields

NCT03642080 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2018-12-19

No results posted yet for this study

Summary

Patients with glioblastoma, an aggressive brain tumor, are recommended to undergo treatment with tumor treating fields using the Optune device as part of standard of care therapy. While undergoing treatment, patients are monitored regularly with brain MRI scans to look for tumor progression, but there are currently no means to predict which, or when, patients will progress. The purpose of the current study is to prospectively analyze these MRI scans to look for subtle imaging markers that can predict for future brain tumor progression while undergoing tumor treating field therapy.

Conditions

Sponsors & Collaborators

  • New York Presbyterian Brooklyn Methodist Hospital

    lead OTHER

Principal Investigators

  • Adel Guirguis, MD, MS · New York Presbyterian Hospital - Brooklyn Methodist Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2021-09-30
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03642080 on ClinicalTrials.gov